NCT07179315View on ClinicalTrials.gov

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions

Head and Neck Cancer

Interventions

DRUG

cemiplimab+fianlimab

Fianlimab 1600 mg + Cemiplimab 350 mg FDC

DRUG

Cemiplimab

350 mg

All Listed Sponsors

lead

University of Chicago

OTHER